Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dendritic Cell Vaccination Clear all
Completed Phase 2 Interventional Results available

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

NCT00617409
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA)
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

NCT03927222
View directory record Official record
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 10, 2026, 5:54 PM EDT
Withdrawn Phase 2 Interventional

Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant

NCT02115126
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP2A-loaded conventional DC vaccine, DUK-CPG-001
Biological
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

NCT00622401
View directory record Official record
Conditions
Breast Cancer
Interventions
Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

NCT00082641
View directory record Official record
Conditions
Breast Cancer
Interventions
autologous dendritic cell-adenovirus p53 vaccine
Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional Results available

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

NCT00776295
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

NCT01067287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT-011, Dendritic Cell Fusion Vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

NCT02224599
View directory record Official record
Conditions
Progressive Solid Malignancies, Refractory Solid Malignancies, Cancer
Interventions
TAPA-pulsed DC vaccine, Cyclophosphamide Pill, Imiquimod Topical Cream
Biological · Drug
Lead sponsor
Kiromic BioPharma Inc.
Industry
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional

Combined Modality Treatment for Patients With Stage IV Melanoma

NCT00313235
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine and Cyclophosphamide
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

NCT02018458
View directory record Official record
Conditions
Breast Cancer
Interventions
LA TNBC: DC vaccine+Preop chemo, ER+/HER2-BC:DC vaccine+Preop chemo
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Results available

Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma

NCT03615404
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
Interventions
CMV-DCs with GM-CSF, Td (tetanus toxoid)
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
0 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

NCT00683670
View directory record Official record
Conditions
Melanoma
Interventions
cyclophosphamide, Mature dendritic cell vaccine
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

NCT00050323
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Allogeneic DCs and Autologous RCC Tumor Derived Cells
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 10, 2026, 5:54 PM EDT
Recruiting Phase 3 Interventional

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Results available

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT01995708
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

NCT01410968
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells
Drug
Lead sponsor
Carolyn Britten
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional Results available

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

NCT00799110
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

DC Vaccine in Pancreatic Cancer

NCT03592888
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
mDC3/8-KRAS Vaccine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Phase 1 Interventional

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

NCT01216436
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 10, 2026, 5:54 PM EDT
Terminated Not applicable Interventional

A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3

NCT00001064
View directory record Official record
Conditions
HIV Infections
Interventions
Allogenic Dendritic Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

NCT00625755
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Electrofusion DC vaccine
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 10, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

NCT00056758
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2007 · Synced Sep 10, 2026, 5:54 PM EDT